| Product Code: ETC9960466 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Axicabtagene Ciloleucel Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Axicabtagene Ciloleucel Market - Industry Life Cycle |
3.4 United States (US) Axicabtagene Ciloleucel Market - Porter's Five Forces |
3.5 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume Share, By Dosage, 2021 & 2031F |
3.8 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Axicabtagene Ciloleucel Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in the United States, especially hematologic malignancies, driving the demand for innovative treatments like axicabtagene ciloleucel. |
4.2.2 Rising investments in research and development for advanced cell therapies in the US. |
4.2.3 Supportive regulatory environment and accelerated approval pathways for novel therapies like axicabtagene ciloleucel. |
4.3 Market Restraints |
4.3.1 High cost associated with axicabtagene ciloleucel treatment limiting its accessibility to a broader patient population. |
4.3.2 Limited awareness and understanding among healthcare providers and patients about the benefits and availability of axicabtagene ciloleucel therapy. |
5 United States (US) Axicabtagene Ciloleucel Market Trends |
6 United States (US) Axicabtagene Ciloleucel Market, By Types |
6.1 United States (US) Axicabtagene Ciloleucel Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Miscellaneous Antineoplastic, 2021- 2031F |
6.1.4 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Other, 2021- 2031F |
6.2 United States (US) Axicabtagene Ciloleucel Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Large B-cell Lymphoma, 2021- 2031F |
6.2.3 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Follicular Lymphoma, 2021- 2031F |
6.2.4 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Other, 2021- 2031F |
6.3 United States (US) Axicabtagene Ciloleucel Market, By Dosage |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Suspension, 2021- 2031F |
6.3.3 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Injection, 2021- 2031F |
6.3.4 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Other, 2021- 2031F |
6.4 United States (US) Axicabtagene Ciloleucel Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.4.3 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Other, 2021- 2031F |
6.5 United States (US) Axicabtagene Ciloleucel Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Clinic, 2021- 2031F |
6.5.3 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Hospital, 2021- 2031F |
6.5.4 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Cancer Treatment Center, 2021- 2031F |
6.5.5 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Others, 2021- 2031F |
6.6 United States (US) Axicabtagene Ciloleucel Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.4 United States (US) Axicabtagene Ciloleucel Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 United States (US) Axicabtagene Ciloleucel Market Import-Export Trade Statistics |
7.1 United States (US) Axicabtagene Ciloleucel Market Export to Major Countries |
7.2 United States (US) Axicabtagene Ciloleucel Market Imports from Major Countries |
8 United States (US) Axicabtagene Ciloleucel Market Key Performance Indicators |
8.1 Number of clinical trials and research studies focusing on axicabtagene ciloleucel in the US. |
8.2 Adoption rate of axicabtagene ciloleucel by key cancer treatment centers and hospitals in the US. |
8.3 Patient outcomes and survival rates post-treatment with axicabtagene ciloleucel. |
9 United States (US) Axicabtagene Ciloleucel Market - Opportunity Assessment |
9.1 United States (US) Axicabtagene Ciloleucel Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 United States (US) Axicabtagene Ciloleucel Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 United States (US) Axicabtagene Ciloleucel Market Opportunity Assessment, By Dosage, 2021 & 2031F |
9.4 United States (US) Axicabtagene Ciloleucel Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 United States (US) Axicabtagene Ciloleucel Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 United States (US) Axicabtagene Ciloleucel Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Axicabtagene Ciloleucel Market - Competitive Landscape |
10.1 United States (US) Axicabtagene Ciloleucel Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Axicabtagene Ciloleucel Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here